Research Article

Treatment of Chronic Hepatitis B with Vaccine or Vaccine-Antibody Complex Loaded pDC and mDC


  • İbrahim HATİPOĞLU
  • Duygu ERCAN
  • Soner AKSU
  • İbrahim SÖGÜT
  • Şakir SEKMEN
  • Gazi TURGUT
  • Deniz DURALI
  • Aynur BAŞALP

Viral Hepat J 2013;19(1):27-31

Objective: In this study, we aimed to develop new alternative dendritic cell (DC) vaccine by using synergic effect of between vaccine or vaccine-antibody loaded plasmacytoid dendritic cell (pDC) and conventional DC/myeloid DC (cDC/mDC) to treat chronic hepatitis B. Materials and Methods: pDCs and mDCs derived from bone marrow of chronic hepatitis B model (HBV-tg) mice in the presence of flt-3L in in vitro and loaded with vaccine or vaccine-antibody complex and then HBV-tg mice were immunized intraperitoneally two times at two weeks intervals. Anti-HBsAg response was detected by ELISA, decrease of HBV DNA was investigated by RT-qPCR. Results: At day 8, flow cytometry analyses have shown that the frequency of mDCs was about 65% and pDC was about 35%. Anti-HBsAg response was induced in HBV-tg mice but it was not significant statistically and we did not detected decrease of HBV DNA in plasma. Conclusion: Even though pDC and mDC were derived from bone marrows, vaccine or vaccine-antibody complex may protect synergic effect between DCs. (Viral Hepatitis Journal 2013; 19(1): 27-31)

Keywords: Dendritic cell vaccine, chronic hepatitis B; hepatitis B vaccine, vaccine-antibody complex

Full Text (Turkish)